Status:
COMPLETED
Provigil (Modafinil) Study by Taiwan Biotech Co.
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Narcolepsy
Cataplexy
Eligibility:
All Genders
12-65 years
Phase:
NA
Brief Summary
The primary objective is to evaluate the therapeutic effect of excessive daytime sleepiness associated with narcolepsy. Both of the subjective and objective sleepiness of the patients were assessed in...
Eligibility Criteria
Inclusion
- Polysomnographic findings of shortened sleep latency less than 5 minutes average of Multiple Sleep Latency Test, and two or more SOREM should be fulfilled.
- Age of 12 y/o to 55 y/o.
- The liver and kidney functions are within normal limits.
- Meeting the strict criteria of narcolepsy described above.
- Wash out any medications which might enhance wakefulness or affect nocturnal sleep two weeks prior to the experiments.
- Willingness to comply with the protocol and signed the written Informed Consent.
Exclusion
- Patients whose hypersomnia was caused by severely sleep deprived, phase delayed, or suspected long sleeper.
- Patients with concomitant neurological disorder and psychiatric disorders.
- Patients with sleep-related breathing disorders whose apnea/hypopnea index (AHI) was 5 pauses per hour above.
- Patients with Restless Leg Syndrome \& Periodic Limbs Movements whose index was more than 5 per hour.
- Patients who are pregnant or breast-feeding.
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00174174
Start Date
September 1 2003
Last Update
September 15 2005
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.